Thelansis

 Platinum-resistant ovarian cancer, characterized by a grim prognosis and limited treatment choices, represents a challenging subtype of ovarian cancer. It is identified by the reappearance of the disease within six months after a platinum-based chemotherapy regimen is completed. The development of resistance to platinum compounds involves intricate mechanisms, and approximately 25% of women with ovarian cancer naturally exhibit resistance to platinum treatments. While many patients initially respond well to frontline platinum therapy, they often experience disease recurrence and gradually acquire resistance over time. For the past three decades, platinum-based chemotherapy has stood as the standard care for ovarian cancer. Nevertheless, some patients eventually develop resistance to platinum in recurrent cases of the disease. Currently, the primary therapeutic approach for platinum-resistant recurrent ovarian cancer patients involves systemic chemotherapy, including agents like po...